Navigation Links
Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
Date:1/3/2008

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the development of, and potential market for, sugammadex. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward- looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A, "R
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)...  Lisa Kulik saw fireworks for the first time ... to a groundbreaking retinal implant co-invented by Mark ... the University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative ... June 2, she became the first person west of ...
(Date:8/27/2014)... Mass. (PRWEB) August 27, 2014 “We ... top technology vendors,” said Ven Thangaraj, CEO of Radiant ... solutions that are taking the imaging corelab market to ... sponsors, corelabs and research organizations to efficiently and effectively ... prepare the data to be analyzed and read by ...
(Date:8/27/2014)... Reportbuyer.com has added a new market ... A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds graphene, ... to water treatment, but is graphene the only ... Graphene Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Enzyme for Pulp & Paper Industry Report 2014" ... Enzyme for Pulp & Paper Industry Report 2014 is ... of the global enzyme for pulp & paper industry. ... the industry including definitions, classifications, applications and industry chain ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Novavax, Inc. (Nasdaq:,NVAX) Novavax today announced Chief Executive Officer ... Healthcare Conference at,5:05 am Eastern time (11:05 am CEST) ... Monaco, the company announced today., Dr. Singhvi will ... progress and its unique manufacturing solution. A,link to an ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced ... for Oxyglobin(R) solution [hemoglobin glutamer-200,(bovine)] or HBOC-301, in ... canine anemia, a potentially life-threatening condition.,Under the terms ... 60 mL,single dose and 125 mL single dose ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today reported ... 31, 2008., "We had a productive start ... refocusing our operations to advance four high-value,programs," said ... recent decision to license R3487/MEM 3454 highlights the ...
Cached Biology Technology:Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 2Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 3Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 4Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 5Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 6Memory Pharmaceuticals Reports First Quarter 2008 Financial Results 7
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the Genetics Society of America,s 27th ... October 3, 2014 in Pacific Grove, California. ... entry of students, post doctorates and scientists from ... science community and to encourage the participation of ...
(Date:8/28/2014)... DURHAM, N.C. -- Scientists have identified the developmental on-off ... microbes that produce more than two-thirds of the world,s ... would be to see whether it is possible to ... efficient. , The study, appearing August 28 in ... a small molecule called cyclic-di-GMP and a larger protein ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... UPTON, NY Hydrogen gas offers one of the ... But traditional methods of producing pure hydrogen face significant ... harmful carbon dioxide into the atmosphere or requiring rare ... scientists at the U.S. Department of Energy,s (DOE) Brookhaven ...
... press release is available in German . ... more,autonomy and far more freedom of discretion. Today, the ... a result of which KIT will be principal of ... future. In,addition, KIT will have the right to make ...
... rats demonstrates that the anti-epilepsy drug phenobarbital stunts neuronal ... first-line drug to treat epilepsy in human newborns. ... May 11, researchers at Georgetown University Medical Center (GUMC) ... pups about a week old changed the way the ...
Cached Biology News:Low-cost nanosheet catalyst discovered to split hydrogen from water 2Low-cost nanosheet catalyst discovered to split hydrogen from water 3Low-cost nanosheet catalyst discovered to split hydrogen from water 4More freedom of discretion for KIT 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3
... This product is designed to deparaffinize and ... formalin fixed paraffin-embedded tissue sections mounted on ... melting the paraffin at the high temperature ... with emulsification of the paraffin by detergent. ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
NEWBORN CALF SERUM AND PLASMA...
...
Biology Products: